Solna, Sweden, May 21, 2026. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies, today announced the appointment of Stefan Larsson, MD, PhD, and Raj Shah, MD, as additional non-executive directors to its Board of Directors, effective April 28th. The appointments further strengthen scientific, operational and transactional expertise to the Board as the Company progresses dose escalation in its ODIN Phase 1/2 study of TH9619 as monotherapy in solid tumors and prepares for its next stage of growth.
The additions follow a period of strong execution for One-carbon Therapeutics, including the dosing of the first subject in the ODIN Phase 1/2 study, the closing of an oversubscribed SEK 153 million (€13.9 million) private placement, and a strategic molecular collaboration with Tempus. Dr Larsson and Dr Shah will contribute to shaping the Company’s clinical development strategy and its trajectory toward institutional financing.
“We are delighted to welcome Stefan and Raj as new members off our Board at this pivotal moment for One-carbon Therapeutics,” said Ana Slipicevic, Chief Executive Officer of One-carbon Therapeutics. “Stefan’s clinical insight and his lifelong focus on outcomes that matter to subjects directly reinforce our disciplined, data-driven development approach. Raj’s experience across healthcare investing, banking and clinical practice will be instrumental as we deliver against our milestones and engage with the next generation of partners and investors. Under the efficient leadership of our Chairman, Antoine Yver, the board brings exactly the perspectives we need as we translate our science into clinical impact.”
About the new Board members
Stefan Larsson, MD, PhD
Dr. Larsson trained at the Karolinska Institute (KI), Harvard Medical School and the MRC Human Genetics Unit in Edinburgh, and is an Associate Professor at KI. He spent 25 years with the Stockholm office of The Boston Consulting Group (BCG), where he founded and first led BCG’s global Payer and Provider sector and its Health Systems sector, and led BCG’s work on value-based health care. He is co-founder and Board Chair of the International Consortium for Health Outcomes Measurement (ICHOM), and a Distinguished Fellow with the World Economic Forum’s Health and Healthcare group. His book The Patient Priority was published by McGraw Hill in November 2022. Dr. Larsson has authored more than 30 peer-reviewed scientific publications and serves as a board member of Industrifonden, Symcel AB and Caneon AB.
Raj Shah, MD
Dr. Shah is Partner and Head of Healthcare at Nordic Capital Advisors, a position he has held since 2015, and brings over 30 years of experience across the healthcare industry. He holds several non-executive positions and serves on the board of several of Nordic Capital’s most significant portfolio investments. His healthcare experience spans both clinical practice, having initially qualified and practised as a cardiac surgeon at Oxford, and extensive transactional experience gained as Co-Head of Goldman Sachs’ healthcare investment banking practice, where he advised private equity and corporate clients.
About One-carbon Therapeutics
One-carbon Therapeutics AB is a clinical-stage precision oncology company pioneering novel cancer therapies built on a deep understanding of cancer biology. Its lead program, TH9619 is a first-in-class, potent small-molecule inhibitor of MTHFD1 and MTHFD2, overexpressed enzymes in cancer cells. This inhibition induces toxic folate trapping, starving tumors of thymidine, a critical DNA building block, leading to DNA damage, thereby causing cancer cell death. By combining strong mechanistic insight with rigorous clinical development, One-carbon Therapeutics aims to advance potent anti-tumor activity while maintaining improved tolerability for patients with solid tumors.
The company is headquartered in Sweden and is committed to translating cutting-edge science into transformative clinical impact for subjects worldwide.